SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Up 84.6% in February

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 125,000 shares, a growth of 84.6% from the February 13th total of 67,700 shares. Based on an average trading volume of 126,400 shares, the short-interest ratio is presently 1.0 days. Currently, 1.7% of the company’s stock are sold short.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Northern Trust Corp bought a new position in shares of SAB Biotherapeutics during the 4th quarter valued at approximately $43,000. Diadema Partners LP bought a new position in SAB Biotherapeutics in the 4th quarter worth approximately $114,000. Geode Capital Management LLC boosted its holdings in SAB Biotherapeutics by 18.8% in the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock worth $307,000 after buying an additional 12,692 shares during the period. HB Wealth Management LLC boosted its holdings in SAB Biotherapeutics by 118.6% in the 4th quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock worth $982,000 after buying an additional 128,800 shares during the period. Finally, Kovitz Investment Group Partners LLC bought a new position in SAB Biotherapeutics in the 3rd quarter worth approximately $52,000. 7.82% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a report on Wednesday, January 29th. Chardan Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of SAB Biotherapeutics in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $12.40.

SAB Biotherapeutics Trading Down 1.2 %

Shares of SAB Biotherapeutics stock traded down $0.02 on Friday, reaching $1.61. 87,385 shares of the company traded hands, compared to its average volume of 60,287. SAB Biotherapeutics has a 52 week low of $1.45 and a 52 week high of $6.30. The company has a 50 day moving average of $2.45 and a 200 day moving average of $2.92. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.